These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 16626892)

  • 41. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience.
    Lee B; Shinohara K; Weinberg V; Gottschalk AR; Pouliot J; Roach M; Hsu IC
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1106-12. PubMed ID: 17197119
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer.
    Tharp M; Hardacre M; Bennett R; Jones WT; Stuhldreher D; Vaught J
    Brachytherapy; 2008; 7(3):231-6. PubMed ID: 18579446
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
    Ares C; Popowski Y; Pampallona S; Nouet P; Dipasquale G; Bieri S; Ozsoy O; Rouzaud M; Khan H; Miralbell R
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):656-63. PubMed ID: 19250768
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reduction of pulmonary migration of permanent interstitial sources in patients undergoing prostate brachytherapy.
    Stone NN; Stock RG
    Urology; 2005 Jul; 66(1):119-23. PubMed ID: 15992909
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Initial comparison of inverse optimization, modified peripheral technique, and geometric optimization as real-time intraoperative computer planning options for permanent seed implantation of the prostate.
    Raben A; Sammons S; Sim S; Chen H; Hanlon A; Sarkar A; Donavanik V; Grebler A; Geltzeiler J; Benge B; Glick A; Jacob D; Koprowski P
    Brachytherapy; 2007; 6(4):238-45. PubMed ID: 17991621
    [TBL] [Abstract][Full Text] [Related]  

  • 47. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103.
    Rivard MJ; Butler WM; Devlin PM; Hayes JK; Hearn RA; Lief EP; Meigooni AS; Merrick GS; Williamson JF
    Brachytherapy; 2007; 6(1):34-7. PubMed ID: 17284383
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dosimetry of anal radiation in high-dose-rate brachytherapy for prostate cancer.
    Kälkner KM; Bengtsson E; Eriksson S; Holmberg C; Nilsson S; Levitt S; Lundell M
    Brachytherapy; 2007; 6(1):49-52. PubMed ID: 17284386
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anisotropy characterization of I-125 seed with attached encapsulated cobalt chloride complex contrast agent markers for MRI-based prostate brachytherapy.
    Frank SJ; Tailor RC; Kudchadker RJ; Martirosyan KS; Stafford RJ; Elliott AM; Swanson DA; Sing D; Choi J; Mourtada F; Ibbott GS
    Med Dosim; 2011; 36(2):200-5. PubMed ID: 20537886
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of dosimetric and biologic effective dose parameters for prostate and urethra using 131 Cs and 125 I for prostate permanent implant brachytherapy.
    Sahgal A; Jabbari S; Chen J; Pickett B; Roach M; Weinberg V; Hsu IC; Pouliot J
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):247-54. PubMed ID: 18722275
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Feasibility of adequate dose coverage in permanent prostate brachytherapy using divergent needle insertion methods.
    van den Bosch MR; Lips IM; Lagerburg V; van Vulpen M; Lagendijk JJ; Moerland MA
    Radiother Oncol; 2008 Jan; 86(1):120-5. PubMed ID: 18037520
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma.
    Nurani R; Wallner K; Merrick G; Virgin J; Orio P; True LD
    J Urol; 2007 Nov; 178(5):1968-73; discussion 1973. PubMed ID: 17868717
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure].
    Toledano A; Chauveinc L; Flam T; Thiounn N; Solignac S; Timbert M; Rosenwald JC; Cosset JM
    Cancer Radiother; 2007 May; 11(3):105-10. PubMed ID: 17158082
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dynamic dose-feedback prostate brachytherapy in patients with large prostates and/or planned transurethral surgery before implantation.
    Acher PL; Popert R; Morris SL; Potters L; Austin-Smith SL; Johnson UH; Nichol JE; Beaney RP
    BJU Int; 2007 May; 99(5):1066-71. PubMed ID: 17233801
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone.
    Papagikos MA; Rossi PJ; Urbanic JJ; deGuzman AF; McCullough DL; Clark PE; Lee WR
    Am J Clin Oncol; 2007 Apr; 30(2):199-204. PubMed ID: 17414471
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A dosimetric analysis of unstranded seeds versus customized stranded seeds in transperineal interstitial permanent prostate seed brachytherapy.
    Heysek RV; Gwede CK; Torres-Roca J; Cantor A; Kelley S; Saini AS; Pow-Sang J
    Brachytherapy; 2006; 5(4):244-50. PubMed ID: 17118318
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prostate brachytherapy post-implant dosimetry: a comparison between higher and lower source density.
    Thomas CW; Kruk A; McGahan CE; Spadinger I; Morris WJ
    Radiother Oncol; 2007 Apr; 83(1):18-24. PubMed ID: 17368844
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: a critical review.
    van der Wielen GJ; Mulhall JP; Incrocci L
    Radiother Oncol; 2007 Aug; 84(2):107-13. PubMed ID: 17707936
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sequential comparison of seed loss and prostate dosimetry of stranded seeds with loose seeds in 125I permanent implant for low-risk prostate cancer.
    Saibishkumar EP; Borg J; Yeung I; Cummins-Holder C; Landon A; Crook J
    Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):61-8. PubMed ID: 18823713
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy.
    Stone NN; Potters L; Davis BJ; Ciezki JP; Zelefsky MJ; Roach M; Shinohara K; Fearn PA; Kattan MW; Stock RG
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):341-6. PubMed ID: 18597953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.